These results also provide a possible explanation for the enhanced anti-proliferative effect of the combination of HDACi and 5-aza-CdR (a DNMT1 inhibitor) on pancreatic cancer cells35 because cancer cells with lower DNMT1 expression are more sensitive to 5-aza-CdR treatment34. The gene discussed is DNMT1; the disease is pancreatic neoplasm.